Eupraxia Pharmaceuticals (EPRX) Receivables - Other (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 5 years of Receivables - Other data on file, last reported at $663235.0 in Q1 2026.

• On a quarterly basis, Receivables - Other rose 178.05% year-over-year to $663235.0 in Q1 2026; TTM through Mar 2026 was $663235.0, a 178.05% increase from a year earlier, with the FY2025 full-year figure at $674226.0, up 194.59% from the prior year.
• Receivables - Other for Q1 2026 stood at $663235.0, down from $674226.0 in the prior quarter.
• Over the last five years, Receivables - Other for EPRX reached as high as $674226.0 in Q4 2025 and fell as low as $89715.0 in Q4 2022.
• Historically, Receivables - Other has averaged $253464.5 across 5 years, with a median of $167243.0 in 2024.
• On a YoY basis, Receivables - Other climbed as much as 194.59% in 2025 and fell as far as 13.29% in 2025.
• Year by year, Receivables - Other stood at $89715.0 in 2022, then soared by 112.46% to $190612.0 in 2023, then advanced by 20.07% to $228872.0 in 2024, then surged by 194.59% to $674226.0 in 2025, then retreated by 1.63% to $663235.0 in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $663235.0 in Q1 2026, $674226.0 in Q4 2025, and $139904.0 in Q3 2025.